204 related articles for article (PubMed ID: 36452303)
21. Urinary microbiome community types associated with urinary incontinence severity in women.
Carnes MU; Siddiqui NY; Karstens L; Gantz MG; Dinwiddie DL; Sung VW; Bradley M; Brubaker L; Ferrando CA; Mazloomdoost D; Richter HE; Rogers RG; Smith AL; Komesu YM;
Am J Obstet Gynecol; 2024 Mar; 230(3):344.e1-344.e20. PubMed ID: 38937257
[TBL] [Abstract][Full Text] [Related]
22. Comparative Efficacy and Tolerability of Antimuscarinic Agents and the Selective β3-Adrenoceptor Agonist, Mirabegron, for the Treatment of Overactive Bladder: Which is More Preferable as an Initial Treatment?
Kobayashi M; Nukui A; Kamai T
Low Urin Tract Symptoms; 2018 May; 10(2):158-166. PubMed ID: 28009939
[TBL] [Abstract][Full Text] [Related]
23. Adding mirabegron after intravesical onabotulinumtoxinA injection improves therapeutic effects in patients with refractory overactive bladder.
Wang CC; Lee CL; Hwang YT; Kuo HC
Low Urin Tract Symptoms; 2021 Oct; 13(4):440-447. PubMed ID: 33960119
[TBL] [Abstract][Full Text] [Related]
24. The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with α1-adrenergic receptor blocker monotherapy: prospective analysis of elderly men.
Matsuo T; Miyata Y; Kakoki K; Yuzuriha M; Asai A; Ohba K; Sakai H
BMC Urol; 2016 Jul; 16(1):45. PubMed ID: 27473059
[TBL] [Abstract][Full Text] [Related]
25. Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER).
Herschorn S; Staskin D; Tu LM; Fialkov J; Walsh T; Gooch K; Schermer CR
Health Qual Life Outcomes; 2018 Apr; 16(1):69. PubMed ID: 29673355
[TBL] [Abstract][Full Text] [Related]
26. Defining the relationship between vaginal and urinary microbiomes.
Komesu YM; Dinwiddie DL; Richter HE; Lukacz ES; Sung VW; Siddiqui NY; Zyczynski HM; Ridgeway B; Rogers RG; Arya LA; Mazloomdoost D; Levy J; Carper B; Gantz MG;
Am J Obstet Gynecol; 2020 Feb; 222(2):154.e1-154.e10. PubMed ID: 31421123
[TBL] [Abstract][Full Text] [Related]
27. Effect of mirabegron on erectile function in sexually active men with bothersome overactive bladder symptoms.
Wu TH; Shen YC; Lee WC; Wang HJ; Chuang YC
J Chin Med Assoc; 2020 Jan; 83(1):55-59. PubMed ID: 31567878
[TBL] [Abstract][Full Text] [Related]
28. Safety and effectiveness of mirabegron in patients with overactive bladder aged ≥75 years: Analysis of a Japanese post-marketing study.
Yoshida M; Nozawa Y; Kato D; Tabuchi H; Kuroishi K
Low Urin Tract Symptoms; 2019 Jan; 11(1):30-38. PubMed ID: 28901041
[TBL] [Abstract][Full Text] [Related]
29. Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II).
Gratzke C; van Maanen R; Chapple C; Abrams P; Herschorn S; Robinson D; Ridder A; Stoelzel M; Paireddy A; Yoon SJ; Al-Shukri S; Rechberger T; Mueller ER
Eur Urol; 2018 Oct; 74(4):501-509. PubMed ID: 29866467
[TBL] [Abstract][Full Text] [Related]
30. Patient-reported outcomes with the β
Khullar V; Amarenco G; Angulo JC; Blauwet MB; Nazir J; Odeyemi IA; Hakimi Z
Neurourol Urodyn; 2016 Nov; 35(8):987-994. PubMed ID: 26288118
[TBL] [Abstract][Full Text] [Related]
31. Safety and effectiveness of mirabegron in male patients with overactive bladder with or without benign prostatic hyperplasia: A Japanese post-marketing study.
Takahashi S; Kato D; Tabuchi H; Uno S
Low Urin Tract Symptoms; 2021 Jan; 13(1):79-87. PubMed ID: 32761776
[TBL] [Abstract][Full Text] [Related]
32. Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.
Chapple CR; Cruz F; Cardozo L; Staskin D; Herschorn S; Choudhury N; Stoelzel M; Heesakkers J; Siddiqui E
Eur Urol; 2020 Jan; 77(1):119-128. PubMed ID: 31635815
[TBL] [Abstract][Full Text] [Related]
33. A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study).
Yamanishi T; Kaga K; Sakata K; Yokoyama T; Kageyama S; Fuse M; Tokunaga S
Neurourol Urodyn; 2020 Feb; 39(2):804-812. PubMed ID: 31961963
[TBL] [Abstract][Full Text] [Related]
34. Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a β₃-adrenoceptor agonist (Mirabegron) for overactive bladder (OAB).
Rossanese M; Novara G; Challacombe B; Iannetti A; Dasgupta P; Ficarra V
BJU Int; 2015 Jan; 115(1):32-40. PubMed ID: 24602031
[TBL] [Abstract][Full Text] [Related]
35. A multicenter prospective study for overactive bladder patient treatment satisfaction with mirabegron after being unsatisfied with antimuscarinic therapy (FAVOR study).
Ko KJ; Choo MS; Chang YS; Kim JC; Lee KS
Neurourol Urodyn; 2020 Nov; 39(8):2417-2424. PubMed ID: 32894793
[TBL] [Abstract][Full Text] [Related]
36. Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE).
Carlson KV; Rovner ES; Nair KV; Deal AS; Kristy RM; Schermer CR
Adv Ther; 2019 Aug; 36(8):1906-1921. PubMed ID: 31222714
[TBL] [Abstract][Full Text] [Related]
37. Altered gut microbiome associated with overactive bladder and daily urinary urgency.
Okamoto T; Hatakeyama S; Imai A; Yamamoto H; Yoneyama T; Mori K; Yoneyama T; Hashimoto Y; Nakaji S; Ohyama C
World J Urol; 2021 Mar; 39(3):847-853. PubMed ID: 32419054
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of pelvic floor magnetic stimulation combined with mirabegron in female patients with refractory overactive bladder: a prospective study.
Liang P; Tang QL; Lin T; Tang ZK; Liu FD; Zhou XZ; Tao RZ
Front Neurosci; 2024; 18():1373375. PubMed ID: 38660220
[TBL] [Abstract][Full Text] [Related]
39. Urinary Microbiome of Reproductive-Age Asymptomatic European Women.
Ugarcina Perovic S; Ksiezarek M; Rocha J; Cappelli EA; Sousa M; Ribeiro TG; Grosso F; Peixe L
Microbiol Spectr; 2022 Dec; 10(6):e0130822. PubMed ID: 36383025
[TBL] [Abstract][Full Text] [Related]
40. The translation and validation of Chinese overactive bladder symptom score for assessing overactive bladder syndrome and response to solifenacin treatment.
Chou EC; Hung MJ; Yen TW; Chuang YC; Meng E; Huang ST; Kuo HC
J Formos Med Assoc; 2014 Aug; 113(8):506-12. PubMed ID: 25037757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
